CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioSpace
Original article

Despite chaos and churn, FDA decisions hold mostly steady in H1 2026

RegulatoryNeutral
AI Analysis

Summary

The FDA experienced leadership instability and workforce attrition in H1 2026, causing a slight slowdown in regulatory productivity, though the agency has recently been catching up.

Importance:2/10
Sentiment:
0.00
FDAregulatory_productivityleadershipworkforce

Read the original article

Published by BioSpace on July 6, 2026 4:01 AM

Read Original